sulfaphenazole has been researched along with diphenhydramine in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fetzer, L; Frotscher, M; Hartmann, RW; Kruchten, P; Marchais-Oberwinkler, S; Messinger, J; Müller-Vieira, U; Neugebauer, A; Scherer, C; Thole, H; Ziegler, E | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Frotscher, M; Hartmann, RW; Henn, C; Kruchten, P; Marchais-Oberwinkler, S; Werth, R; Wetzel, M; Ziegler, E | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
5 other study(ies) available for sulfaphenazole and diphenhydramine
Article | Year |
---|---|
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent disease
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Aryl Hydrocarbon Hydroxylases; Binding Sites; Caco-2 Cells; Computer Simulation; Drug Design; Enzyme Inhibitors; Estrogens; Humans; Hydrogen Bonding; Liver; Male; Microsomes, Liver; Models, Molecular; Molecular Structure; Naphthalenes; Neoplasms, Hormone-Dependent; Quinolines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.
Topics: 17-Hydroxysteroid Dehydrogenases; Administration, Oral; Animals; Biological Availability; Cell Line, Tumor; Cell Membrane Permeability; Cell-Free System; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Liver; Male; Microsomes; Molecular Mimicry; Naphthols; Phenols; Placenta; Pregnancy; Rats; Rats, Sprague-Dawley; Rats, Wistar; Recombinant Proteins; Steroids; Structure-Activity Relationship | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |